Survey on Belgian Patients Suffering From Irregular Heartbeat and Starting Treatment With a Drug to Prevent Blood Clots in Blood Vessels and the Heart. This Study is Also Called BELANCOS.

BELgian ANtiCOagulation Survey for NVAF Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04183270

Acronym

BELANCOS

Enrollment

164

Registered

2019-12-03

Start date

2020-02-10

Completion date

2020-12-31

Last updated

2021-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

In this study researchers want to learn more about the patient's and treating doctor's concerns about possible bleedings during treatment with drugs preventing blood clots in blood vessels and the heart - so called blood thinner. The study also wants to find out more about the patient's knowledge on the importance, risks and benefits of treatment with this drug group. Patients with irregular heartbeat not caused by valvular heart disease who will start treatment with a blood thinner will be asked by their treating cardiologist to complete a questionnaire related to their knowledge and fear of possible bleedings or stroke (blockage or rupture of a blood vessel to the brain) due to the intake of a blood thinner. The treating doctor will complete a similar questionnaire. The study plans to involve 15 cardiologists and 300 patients in Belgium.

Interventions

OTHERQuestionnaires

The survey will focus on non-valvular atrial fibrillation patients, who will start treatment with a NOAC, and their treating physician.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or female adult patients diagnosed with NVAF. * NOAC treatment-naive patients who will start a NOAC treatment.

Exclusion criteria

* Previous stroke or thrombosis * Previous severe bleeding

Design outcomes

Primary

Measure	Time frame	Description
Level of patients fear of having a bleeding assessed by physicans on a scale from 0 - 10	1 day	—
Physicans' level of agreement with various statement of using NOACs in general	1 day	By using a 5-point Likert scale (completely disagree, more likely to disagree, no opinion, more likely to agree, completely agree)
Age categories of physicians	1 day	Collected via the questionnaire.
Gender (Female or male) of physicians	1 day	Collected via the questionnaire.
Age categories of patients	1 day	Collected via the questionnaire.
Gender (Female or male) of patients	1 day	Collected via the questionnaire.
Patients' level of agreement with various statements of using NOACs in general	1 day	By using a 5-point Likert scale (completely disagree, more likely to disagree, no opinion, more likely to agree, completely agree)
Level of patients fear of having a bleeding on a scale from 0 - 10	1 day	—
Level of patients fear of having a stroke or thrombosis on a scale from 0 - 10	1 day	—
Level of patients fear of having a stroke or thrombosis assessed by physicians on a scale from 0 - 10	1 day	—

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026